Welcome : Guest

HUNTINGTON'S DISEASE THERAPEUTICS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Huntington's Disease Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as -

Alnylam Pharmaceuticals, Inc.
Auspex Pharmaceuticals, Inc.
Intellect Neurosciences Incorporation
Lundbeck A/S
Prana Biotechnology Limited

Click here to request a full list of companies covered in the report...

Code: MCP-6280
Price: $4500
Companies: 25
Pages: 122
Date: March 2015
Market Data Tables: 22
  Status: * New Report



TABLE OF CONTENTS


  HUNTINGTON'S DISEASE THERAPEUTICS (Complete Report) Pages : 122   | $4500

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   A Prelude.....II-1
Current HD Treatment.....II-1
1$100
   Huntington’s Disease – Quick Facts.....II-21$100
   Market Opportunity.....II-3
Huntington’s Disease Prevalence in Major Region/Countries.....II-3
Competition in the Global HD Therapeutics Market is Non-existent.....II-3
1$100
   Effectiveness of Current HD Management Strategies.....II-41$100
   HD Treatment and Drugs: Brief Description of Disorder, Medication and
  Side-Effects.....II-5
Alternative Treatment Approaches for Huntington’s Disease.....II-5
1$100
   Alternate Approaches and Therapies.....II-6
Off-Label Prescriptions.....II-6
Select Off-Label Drugs Prescribed for Huntington’s Disease: Drug Name & Manufacturer;
  Treatment Class; and Primary Indication.....II-6
1$100
   mHtt Aggregates in HD—Molecular Pathogenesis.....II-71$100
   Therapeutics Focus on Reduction of mHtt Expression.....II-8
Companies Boost R&D Spending for HD Therapeutics.....II-8
Improved Diagnostics Fueling Interest of Companies in HD Research.....II-8
1$100
   Support Organizations Play an Instrumental Role in HD Research and Awareness.....II-9
Public-Private Partnerships: A Shot in the Arm.....II-9
HD Research Attracts 'Big Pharma' Investment.....II-9
1$100
   Pre-Symptomatic Patients to Expand Market Base.....II-10
HDSA Pushes for Improvement in Medicare Funding for Huntington’s Disease.....II-10
1$100
   GINA for Reducing Discrimination Faced by People with HD.....II-111$100
   A Quick Primer.....II-12
Drug Development Pipeline Reveals a Promising Picture.....II-12
Select Drugs and Supplements in HD Research Pipeline (2014): Drug Name, Manufacturer,
  Mode of Action and Current Status.....II-12
1$100
   An Overview of Select Drugs in Late-Stage Clinical Trials.....II-13
SD-809.....II-13
RP103 (Procysbi).....II-13
PBT2.....II-13
1$100
   Huntexil™ (Pridopidine).....II-141$100
   Other Novel Approaches for HD Treatment.....II-15
Cellular Delivery of Neurotropic Agents.....II-15
Cogane.....II-15
1$100
   COPREXA.....II-16
Histone Deacetylases (HDAC).....II-16
Melatonin, Coenzyme Q-Free Radical Scavengers.....II-16
RNAi - RNA Interference.....II-16
1$100
   Triglyceride Oil ‘Triheptanoin’ Shows Promise for HD Therapeutics.....II-17
Reducing mTORC1 Activation through Drug/Diet May be Helpful.....II-17
Better Understanding of Early Neuronal Changes Lead to Targeted Drug
  Development.....II-17
Lund University Researchers Successfully Map Functionality of Hypothalamus in
  HD.....II-17
1$100
   MIB, University of Lisbon and University of Leicester Demonstrate Latest Findings on
  KMO Enzyme.....II-18
Latest TRACK-HD Findings Demonstrate Early Identification of Huntington's Disease
  Progression in Patients.....II-18
Researchers at BUSM, MGH, Columbia University and McLean BTRC Demonstrate Impact of
  Huntington's Disease on Human Brain.....II-18
1$100
   Researchers Demonstrate Significance of TFEB and PGC-1alpha Proteins in Prevention of
  HD.....II-19
Florey Neuroscience Institutes Demonstrates Importance of Cognitive Stimulation in HD
  Patients.....II-19
1$100
   University of Wisconsin-Madison Waisman Center Demonstrates Stem Cell Therapy Potential
  for Treating HD.....II-20
NUI Galway Announces Discovery of Experimental Drugs with Potential for Slowing
  Progress of HD.....II-20
Lawrence Berkeley National Laboratory Designs Compound for Suppressing HD
  Symptoms.....II-20
1$100
   Development of HD Affected Human Brain Cells for Investigative Purposes.....II-21
Device Implant in Brain Exhibits Therapeutic Potential for HD.....II-21
1$100
   Sangamo Biosciences on Path to Discover a Therapy for HD.....II-22
Scientists at University of Rochester Medical Center Demonstrate Use of Coenzyme Q10
  for Reduction of Oxidative Damage in HD Patients.....II-22
1$100
   Introduction.....II-23
Historical Background.....II-23
1$100
   Prognosis.....II-24
Stages of HD.....II-24
1$100
   Symptoms and Signs.....II-25
Physical Symptoms.....II-25
1$100
   Emotional Symptoms.....II-26
Mental Symptoms.....II-26
Genetics of Huntington's Disease.....II-26
1$100
   Inheritance.....II-27
Mechanism.....II-27
1$100
   Functions of HTT.....II-28
Effects of mHTT on Cells.....II-28
Macroscopic Effects of mHTT.....II-28
1$100
   Diagnosis of HD.....II-29
Clinical Diagnosis.....II-29
1$100
   Embryonic Diagnosis.....II-30
Differential Diagnosis.....II-30
Diagnostic Tests for Huntington's Disease.....II-30
Confirmatory Diagnostic Test.....II-30
Pre-symptomatic Diagnostic Test.....II-30
Prenatal Diagnostic Test.....II-30
Treatment Options.....II-30
1$100
   Nutrition and Eating.....II-31
Social Activity.....II-31
Speech Therapy.....II-31
Physical Therapy.....II-31
1$100
   Occupational Therapy.....II-32
Medication.....II-32
Molecular Chaperones.....II-32
2$200
   Auspex Reports Favorable Study Results of SD-809.....II-34
Sangamo and Collaborators to Present ZFP Therapeutics® Data.....II-34
Sangamo Presents Positive Preclinical Data of ZFP Therapeutic®.....II-34
Sangamo BioSciences Acquires Ceregene.....II-34
Prana Completes Reach2HD Trial.....II-34
1$100
   Teva Pharmaceuticals Forms Global R&D Collaboration for HD.....II-35
KineMed, Isis and CHDI Foundation Collaborate for HD Therapeutics.....II-35
CHDI Foundation Continues Collaboration with Medtronic.....II-35
Roche Enters into Alliance with Isis Pharmaceuticals.....II-35
Omeros Receives IND Approval for OMS824 for Huntington’s Disease.....II-35
Teva Pharmaceutical Industries Signs Asset Transfer Agreement with NeuroSearch.....II-35
uniQure and Benitec Biopharma Ink Cross-Licensing Agreement.....II-35
1$100
   Evotec and CHDI Foundation Extend Collaboration.....II-36
Raptor Acquires Exclusive Rights to Cysteamine and Associated Compounds.....II-36
GNS Healthcare Enters into Collaboration with CHDI Foundation.....II-36
Lundbeck Collaborates with CHDI Foundation for HD Research.....II-36
Horizon Discovery Collaborates with Institute of Neurology, London.....II-36
Thomson Reuters and CHDI Foundation Enter into MetaMiner Partnership.....II-36
1$100
   Alnylam Pharmaceuticals, Inc. (US).....II-37
Auspex Pharmaceuticals, Inc. (US).....II-37
Intellect Neurosciences Incorporation (US).....II-37
1$100
   Lundbeck A/S (Denmark).....II-38
Prana Biotechnology Limited (Australia).....II-38
Raptor Pharmaceuticals Corp. (US).....II-38
1$100
   Sangamo Biosciences, Inc. (US).....II-39
Teva Pharmaceutical Industries Ltd (Israel).....II-39
Trophos SA (France).....II-39
1$100
   Valeant Pharmaceuticals International, Inc. (Canada).....II-40
Vertex Pharmaceuticals Incorporated (US).....II-40
1$100
   Table 1: World Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....II-411$350
   Table 2: World Historic Review for Huntington's Disease Therapeutics by Geographic Region - US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....II-421$350
   Table 3: World 11-Year Perspective for Huntington’s Disease Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, and Rest of World Markets for the Years 2009, 2015 & 2020 (includes corresponding Graph/Chart).....II-431$350
   A. Market Analysis.....III-1
HDSA Brings about Improved Medicare Funding for Huntington’s Disease.....III-1
GINA for Reducing Discrimination Faced by People with HD.....III-1
1$75
   Strategic Corporate Developments.....III-22$150
   Select Players.....III-42$150
   B. Market Analytics.....III-6
Table 4: The US Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....III-6
1$200
   Table 5: The US Historic Review for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....III-71$200
   Market Analysis.....III-8
Table 6: European Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - France, Germany, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....III-8
1$200
   Table 7: European Historic Review for Huntington's Disease Therapeutics by Geographic Region - France, Germany, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....III-91$200
   Table 8: European 11-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Dollar Revenues for France, Germany, UK, Spain and Rest of Europe Markets for the Years 2009, 2015 & 2020 (includes corresponding Graph/Chart).....III-101$200
   A. Market Analysis.....III-11
Trophos Sa – A Key Player.....III-11
1$75
   B. Market Analytics.....III-12
Table 9: French Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....III-12
1$200
   Table 10: French Historic Review for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....III-131$200
   A. Market Analysis.....III-14
Strategic Corporate Development.....III-14
B. Market Analytics.....III-14
Table 11: German Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....III-14
1$200
   Table 12: German Historic Review for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....III-151$200
   A. Market Analysis.....III-16
Outlook.....III-16
Table 13: Juvenile HD Incidence Estimates in the UK(includes corresponding Graph/Chart).....III-16

Table 14: Juvenile HD Prevalence Estimates in the UK (2006-2010) (includes corresponding Graph/Chart).....III-16
1$200
   Strategic Corporate Development.....III-17
B. Market Analytics.....III-17
Table 15: The UK Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....III-17
1$200
   Table 16: The UK Historic Review for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....III-181$200
   A. Market Analysis.....III-19
KEY PLAYER - SOM BIOTECH.....III-19
1$75
   B. Market Analytics.....III-20
Table 17: Spanish Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....III-20
1$200
   Table 18: Spanish Historic Review for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....III-211$200
   A. Market Analysis.....III-22
Strategic Corporate Development.....III-22
1$75
   B. Market Analytics.....III-23
Table 19: Rest of Europe Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....III-23
1$200
   Table 20: Rest of Europe Historic Review for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....III-241$200
   A. Market Analysis.....III-25
Strategic Corporate Developments.....III-25
Select Players.....III-25
2$150
   B. Market Analytics.....III-27
Table 21: Rest of World Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....III-27
1$200
   Table 22: Rest of World Historic Review for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....III-281$200
  
Total Companies Profiled: 25 

Region/Country Players

The United States 13 Canada 1 Europe 8 France 1 Germany 1 The United Kingdom 2 Italy 1 Rest of Europe 3 Asia-Pacific (Excluding Japan) 3
Click here to request a full table of contents and more details on this project.